Immuneering Corp 8-K

What Happened
Immuneering Corporation (IMRX) filed an 8‑K on June 1, 2026 reporting updated data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) plus modified gemcitabine/nab‑paclitaxel (mGnP) in first‑line pancreatic cancer. As of the April 24, 2026 cutoff (median follow‑up 11.6 months), the 320 mg once‑daily dose cohort (55 patients dosed) showed a median overall survival (mOS) of 17.3 months in the intent‑to‑treat population. The company cited a historical standard‑of‑care mOS of 8.5 months from the third‑party MPACT trial for gemcitabine/nab‑paclitaxel. Median progression‑free survival (mPFS) was 8.3 months; among 50 response‑evaluable patients the overall response rate (ORR) was 36% (18/50) and disease control rate (DCR) was 82% (41/50). Weight stability data (subset) showed 84% of patients either gained weight or remained within 5% of baseline.

Key Details

• Cutoff date: April 24, 2026; median follow‑up: 11.6 months; 55 patients dosed at 320 mg.
• mOS: 17.3 months (320 mg ITT); cited SOC mOS (MPACT trial) = 8.5 months.
• mPFS: 8.3 months; ORR 36% (18/50); DCR 82% (41/50).
• Safety (320 mg ITT): Grade ≥3 treatment‑emergent AEs ≥10% — Neutropenia 18% (10 patients), Anemia 16% (9 patients). Grade ≥3 events <10% included Rash 5%, Fatigue 2%, Vomiting 2%, Peripheral oedema 2%. No Grade 5 events or new safety signals reported.
• Planned milestones: first patient dosed in pivotal Phase 3 MAPKeeper‑301 mid‑2026 (topline mid‑2028); H2‑2026 start atebimetinib + Libtayo® in NSCLC (preliminary data late‑2027); additional preclinical atebimetinib + anti‑PD‑1 data Q4‑2026; IND‑enabling for next program mid‑2027.

Why It Matters
These updated Phase 2a results show a substantially longer mOS in the treated cohort versus the historical MPACT gemcitabine/nab‑paclitaxel benchmark, which—if confirmed in a randomized Phase 3—could represent a meaningful improvement for first‑line pancreatic cancer patients. The filing also signals an accelerated development path: Immuneering expects to begin a pivotal Phase 3 in mid‑2026 and to advance combination and preclinical programs through 2027–2028. Investors should note the trial is not randomized and the mOS comparison is to external, third‑party data; the company expressly cautions against direct cross‑trial comparisons. The 8‑K also contains forward‑looking statements and refers to risk factors in the company’s May 15, 2026 Form 10‑Q.